Q-omics provides the consensus-scored ZNF587 profile across patient tissues and cancer cell-line models. ZNF587 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF587 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF587 RNA expression shows 22,063 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where ZNF587 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF587 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF587 survival associations across molecular data types. ZNF587 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF587 RNA expression–survival associations across cancer types. High ZNF587 expression shows unfavorable associations in MESO, ACC, LGG and CESC, but favorable associations in BRCA and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF587 RNA expression.
This table summarizes ZNF587 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF587. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF587 shows higher tumor expression in HNSC, BLCA, COAD, LUAD, STAD and LIHC. The HNSC box plot shows higher ZNF587 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p < 0.001).
This table shows molecular features associated with ZNF587 in patient tissues and cancer cell lines. In patient samples, ZNF587 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF587 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
